Article
Polygenic scores for major depressive disorder and depressive symptoms predict response to lithium in patients with bipolar disorder
2018-10-22
Abstract excerpt
<h4>Background</h4> Lithium is a first-line medication for bipolar disorder (BD), but only ~30% of patients respond optimally to the drug. Since genetic factors are known to mediate lithium treatment response, we hypothesized whether polygenic susceptibility to the spectrum of depression traits is associated with treatment outcomes in patients with BD. In addition, we explored the potential molecular underpinning...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2745baf7-2cb8-5e77-87f3-cba7e477afac
- DOI
- 10.1101/449363
